HomeFile

File

View Category
Structural heart disease

TAVR in Low-Risk Patients: Though still Superior, with Diminished Advantage after 2 Years.

At two-year followup, primary end point continued to be significantly lower with Sapien 3 vs. conventional surgery,...
solaci -
Learn More
Institutional News

Bulletin 116 ProEducar | Percutaneous Closure of Patent Foramen Ovale

A new edition of the ProEducar Educational Bulletin has arrived for Fellows and interventionists in training. On...
solaci -
Learn More
Antithrombotic Anticoagulants

AAS vs Warfarin in Low Risk TAVR

We are still discussing the adequate antithrombotic scheme after transcatheter aortic valve replacement (TAVR). Additionally, we are...
solaci -
Learn More
Structural heart disease

Improvements in COAPT Trial for Functional Mitral Regurgitation

Patients with heart failure and moderate-to-severe secondary mitral regurgitation may benefit from transcatheter mitral valve repair. There...
solaci -
Learn More
Aorta

Contralateral Occluded Carotid Defines Revascularization Strategy

A significative lesion to the carotid artery in addition to contralateral carotid occlusion is an obvious factor...
solaci -
Learn More
Aorta

Solution for Type 1A Endoleaks After Abdominal Endoprosthesis

Proximal type 1 endoleaks after endovascular abdominal aortic aneurysmal repair are challenging to solve, with no existing...
solaci -
Learn More
Chronic Ischemic cardiopathy

Medical Therapy Optimization Achieved Prior Clinical Trial

12 weeks prior the ORBITA randomization, medical therapy optimization of all antianginal medication was achieved.   Most importantly, optimization...
solaci -
Learn More
Antiplatelet

Net Clinical Benefit of Long-Term Ticagrelor

Ticagrelor reduces ischemic risk in patients with a history of acute myocardial infarction, but it increases the...
solaci -
Learn More